Red Cross Asks FDA To Let False-Positive Blood Donors Back In The Pool
This article was originally published in The Gray Sheet
Executive Summary
FDA should include blood donor re-entry algorithms under investigational new drug applications for nucleic acid test (NAT) screening for hepatitis C (HCV) and HIV, according to the American Red Cross.
You may also be interested in...
Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen
FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.